Last reviewed · How we verify
Wolbachia-carrying Ae.aegypti mosquitoes
Wolbachia-carrying Ae.aegypti mosquitoes is a Biologic drug developed by Universidad de Antioquia. It is currently in Phase 2 development.
At a glance
| Generic name | Wolbachia-carrying Ae.aegypti mosquitoes |
|---|---|
| Sponsor | Universidad de Antioquia |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wolbachia-carrying Ae.aegypti mosquitoes CI brief — competitive landscape report
- Wolbachia-carrying Ae.aegypti mosquitoes updates RSS · CI watch RSS
- Universidad de Antioquia portfolio CI
Frequently asked questions about Wolbachia-carrying Ae.aegypti mosquitoes
What is Wolbachia-carrying Ae.aegypti mosquitoes?
Wolbachia-carrying Ae.aegypti mosquitoes is a Biologic drug developed by Universidad de Antioquia.
Who makes Wolbachia-carrying Ae.aegypti mosquitoes?
Wolbachia-carrying Ae.aegypti mosquitoes is developed by Universidad de Antioquia (see full Universidad de Antioquia pipeline at /company/universidad-de-antioquia).
What development phase is Wolbachia-carrying Ae.aegypti mosquitoes in?
Wolbachia-carrying Ae.aegypti mosquitoes is in Phase 2.